标题
Functional precision cancer medicine—moving beyond pure genomics
作者
关键词
-
出版物
NATURE MEDICINE
Volume 23, Issue 9, Pages 1028-1035
出版商
Springer Nature
发表日期
2017-09-09
DOI
10.1038/nm.4389
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Consensus on precision medicine for metastatic cancers: a report from the MAP conference: Table 1.
- (2016) C. Swanton et al. ANNALS OF ONCOLOGY
- iBH3: simple, fixable BH3 profiling to determine apoptotic priming in primary tissue by flow cytometry
- (2016) Jeremy Ryan et al. BIOLOGICAL CHEMISTRY
- Targeted therapies for CLL: Practical issues with the changing treatment paradigm
- (2016) Nitin Jain et al. BLOOD REVIEWS
- The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice
- (2016) Elizabeth C. Townsend et al. CANCER CELL
- A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds
- (2016) Alejandra Bruna et al. CELL
- Parallel In Vivo Assessment of Drug Phenotypes at Various Time Points during Systemic BRAF Inhibition Reveals Tumor Adaptation and Altered Treatment Vulnerabilities
- (2016) O. Jonas et al. CLINICAL CANCER RESEARCH
- First In Vivo Testing of Compounds Targeting Group 3 Medulloblastomas Using an Implantable Microdevice as a New Paradigm for Drug Development
- (2016) Oliver Jonas et al. Journal of Biomedical Nanotechnology
- Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure
- (2016) Philippe Armand et al. JOURNAL OF CLINICAL ONCOLOGY
- Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)
- (2016) Fabrice Barlesi et al. LANCET
- Precision oncology: origins, optimism, and potential
- (2016) Vinay Prasad et al. LANCET ONCOLOGY
- Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial
- (2016) Anas Younes et al. LANCET ONCOLOGY
- Mitochondria—Judges and Executioners of Cell Death Sentences
- (2016) Patrick D. Bhola et al. MOLECULAR CELL
- Perspective: The precision-oncology illusion
- (2016) Vinay Prasad NATURE
- Drug sensitivity of single cancer cells is predicted by changes in mass accumulation rate
- (2016) Mark M Stevens et al. NATURE BIOTECHNOLOGY
- High-throughput measurement of single-cell growth rates using serial microfluidic mass sensor arrays
- (2016) Nathan Cermak et al. NATURE BIOTECHNOLOGY
- Limits to Personalized Cancer Medicine
- (2016) Ian F. Tannock et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Platform for Rapid, Quantitative Assessment of Multiple Drug Combinations Simultaneously in Solid Tumors In Vivo
- (2016) Joyoti Dey et al. PLoS One
- Precision oncology: a strategy we were not ready to deploy
- (2016) Tito Fojo SEMINARS IN ONCOLOGY
- Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade
- (2016) P.-L. Chen et al. Cancer Discovery
- No Solid Evidence, Only Hollow Argument for Universal Tumor Sequencing
- (2016) Howard (Jack) West JAMA Oncology
- Prospective cohort study using the breast cancer spheroid model as a predictor for response to neoadjuvant therapy – the SpheroNEO study
- (2015) Kathrin Halfter et al. BMC CANCER
- Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia
- (2015) Shuo-Chieh Wu et al. CANCER CELL
- Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy
- (2015) Joan Montero et al. CELL
- Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology
- (2015) Sue Richards et al. GENETICS IN MEDICINE
- Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials
- (2015) Funda Meric-Bernstam et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular Profiling and Targeted Therapy for Advanced Thoracic Malignancies: A Biomarker-Derived, Multiarm, Multihistology Phase II Basket Trial
- (2015) Ariel Lopez-Chavez et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials
- (2015) Maria Schwaederle et al. JOURNAL OF CLINICAL ONCOLOGY
- A Decision Support Framework for Genomically Informed Investigational Cancer Therapy
- (2015) Funda Meric-Bernstam et al. JNCI-Journal of the National Cancer Institute
- Precision medicine: lessons learned from the SHIVA trial
- (2015) Apostolia M Tsimberidou et al. LANCET ONCOLOGY
- Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial
- (2015) Christophe Le Tourneau et al. LANCET ONCOLOGY
- Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice
- (2015) J Etchin et al. LEUKEMIA
- Characteristics of Exceptional or Super Responders to Cancer Drugs
- (2015) Vinay Prasad et al. MAYO CLINIC PROCEEDINGS
- An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors
- (2015) Oliver Jonas et al. Science Translational Medicine
- A technology platform to assess multiple cancer agents simultaneously within a patient’s tumor
- (2015) Richard A. Klinghoffer et al. Science Translational Medicine
- Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testing
- (2015) P O Pietarinen et al. Blood Cancer Journal
- A Decision Support Framework for Genomically Informed Investigational Cancer Therapy
- (2015) Funda Meric-Bernstam et al. JNCI-Journal of the National Cancer Institute
- Prioritizing targets for precision cancer medicine
- (2014) F. Andre et al. ANNALS OF ONCOLOGY
- Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy
- (2014) M. H. Voss et al. CLINICAL CANCER RESEARCH
- Personalized Medicine for Patients with Advanced Cancer in the Phase I Program at MD Anderson: Validation and Landmark Analyses
- (2014) A.-M. Tsimberidou et al. CLINICAL CANCER RESEARCH
- Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
- (2014) Mark G. Kris et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine
- (2014) Eliezer M Van Allen et al. NATURE MEDICINE
- A Targeted Next-Generation Sequencing Assay Detects a High Frequency of Therapeutically Targetable Alterations in Primary and Metastatic Breast Cancers: Implications for Clinical Practice
- (2014) N. Vasan et al. ONCOLOGIST
- Patient-derived models of acquired resistance can identify effective drug combinations for cancer
- (2014) Adam S. Crystal et al. SCIENCE
- Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility
- (2014) M. Yu et al. SCIENCE
- The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints
- (2014) Nicolas J. Llosa et al. Cancer Discovery
- Activating mTOR Mutations in a Patient with an Extraordinary Response on a Phase I Trial of Everolimus and Pazopanib
- (2014) N. Wagle et al. Cancer Discovery
- Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research
- (2014) M. Hidalgo et al. Cancer Discovery
- Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies
- (2014) Bhagwan Yadav et al. Scientific Reports
- Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia
- (2013) R. Pan et al. Cancer Discovery
- Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid Leukemia
- (2013) T. Pemovska et al. Cancer Discovery
- Relative Mitochondrial Priming of Myeloblasts and Normal HSCs Determines Chemotherapeutic Success in AML
- (2012) Thanh-Trang Vo et al. CELL
- Genome Sequencing Identifies a Basis for Everolimus Sensitivity
- (2012) G. Iyer et al. SCIENCE
- Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy
- (2011) T. N. Chonghaile et al. SCIENCE
- Translating cancer research into targeted therapeutics
- (2010) J. S. de Bono et al. NATURE
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
- (2010) Gideon Bollag et al. NATURE
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- (2010) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- ACMG recommendations for standards for interpretation and reporting of sequence variations: Revisions 2007
- (2008) C Sue Richards et al. GENETICS IN MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More